Publications by authors named "Mika Komatsubara"
J Infect Chemother
December 2024
Article Synopsis
- Cefmetazole (CMZ) is being studied as an alternative treatment for infections caused by ESBL-producing bacteria, with this pilot study comparing its effects to meropenem (MP) and a control group with no treatment.
- The study involved collecting feces and saliva samples from patients at different time points to analyze changes in their microbiome due to the antimicrobial treatments.
- Results indicated that meropenem had a more significant negative impact on the fecal microbiome compared to CMZ, especially in the later stages of treatment among Japanese patients.
J Infect Chemother
June 2024
Article Synopsis
- - Tecovirimat's role in treating mpox is still not well-understood, prompting a study in Japan to assess its effectiveness and safety across various patient demographics from June 2022 to April 2023.
- - In the study, 19 male patients (average age 38.5 years), primarily with severe disease and many HIV positive, were treated with tecovirimat; results showed that 60% had negative virus tests in their skin lesions within two weeks, with no severe side effects reported.
- - The findings suggest that starting tecovirimat treatment early can likely shorten the time the virus is detectable, especially in HIV-infected patients, who tend to shed the virus longer, raising the risk of transmission
J Infect Chemother
April 2023
Article Synopsis
- * The first patient was a white man who contracted the virus in Spain, showing symptoms like fever and rash, while the second was a Japanese man who presented with fatigue and other symptoms without a rash after traveling from New York.
- * Both patients were treated with tecovirimat, leading to a quick decline in viral load and discharge from the hospital, indicating the effectiveness of early diagnosis and treatment in preventing broader outbreaks in Japan.
